Type 1 Diabetes Mellitus - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Type 1 Diabetes Mellitus > What Your Doctor is Reading About Type 1 Diabetes Mellitus > Drug Therapy

Drug Therapy

1. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.

Author: Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J;
Institution: The Royal Hospital for Sick Children, Glasgow, UK. kjr@diabetes-scotland.org
Journal: Diabet Med. 2007 Jan;24(1):27-34.
Abstract URL: Click here to view abstract

2. Multisystemic therapy for adolescents with poorly controlled type I diabetes: Stability of treatment effects in a randomized controlled trial.

Author: Ellis DA; Templin T; Naar-King S; Frey MA; Cunningham PB; Podolski CL; Cakan N;
Institution: Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA. dellis@med.wayne.edu
Journal: J Consult Clin Psychol. 2007 Feb;75(1):168-74.
Abstract URL: Click here to view abstract

3. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.

Author: Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W;
Institution: Division of Pediatric Endocrinology and Diabetes, University Children's Hospital, University o f Ulm, Ulm, Germany. beate.karges@uniklinik-ulm.de
Journal: Clin Ther. 2006 Dec;28(12):2094-101.
Abstract URL: Click here to view abstract

4. Long-term use of continuous subcutaneous insulin infusion compared with multiple daily injections of glargine in pediatric patients.

Author: Garcia-Garcia E; Galera R; Aguilera P; Cara G; Bonillo A;
Institution: Department of Pediatrics, "Torrecardenas" Hospital, Almeria, Spain. ggej@hotmail.com
Journal: J Pediatr Endocrinol Metab. 2007 Jan;20(1):37-40.
Abstract URL: Click here to view abstract

5. Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes.

Author: Manini R; Forlani G; Moscatiello S; Zannoni C; Marzocchi R; Marchesini G; Manini R; Forlani G; Moscatiello S; Zannoni C; Marzocchi R; Marchesini G;
Institution: Unit of Metabolic Disease, Alma Mater Studiorum University of Bologna, S. Orsola Hospital, Via Massarenti 9, 40138 Bologna, Italy.
Journal: Nutr Metab Cardiovasc Dis. 2007 Sep;17(7):493-8. Epub 2006 Nov 28.
Abstract URL: Click here to view abstract

6. First approved inhaled insulin therapy for diabetes mellitus.

Author: Jani R; Triplitt C; Reasner C; Defronzo RA; Jani R; Triplitt C; Reasner C; Defronzo RA;
Institution: University of Texas Health Science Center, Diabetes Division, 7703 Floyd Curl Drive, San Antonio, Texas, 78229, USA.
Journal: Expert Opin Drug Deliv. 2007 Jan;4(1):63-76.
Abstract URL: Click here to view abstract

7. Aspart and lispro insulin, is there any difference when used with an insulin pump treatment?

Author: Di Bartolo P; Pellicano F; Scaramuzza A; Fabbri T; Melandri P; Miselli V; Casetti T; Cannata F;
Institution: Diabetes Unit, Department of Digestive and Metabolic Diseases, Local Health Unit of Ravenna, Ravenna, Italy.
Journal: Diabetes Res Clin Pract. 2006 Dec;74 Suppl 2:S119-22.
Abstract URL: Click here to view abstract

8. The renaissance of insulin pump treatment in childhood type 1 diabetes.

Author: Tamborlane WV; Swan K; Sikes KA; Steffen AT; Weinzimer SA;
Institution: General Clinical Research Center, Yale University School of Medicine, New Haven, CT, USA.
Journal: Rev Endocr Metab Disord. 2006 Sep;7(3):205-13.
Abstract URL: Click here to view abstract

9. Insulin pump therapy from the time of diagnosis of type 1 diabetes.

Author: Ramchandani N; Ten S; Anhalt H; Sinha S; Ching J; Finkelstein A; Maclaren NK;
Institution: Department of Pediatrics, Maimonides Medical Center/Infants and Children's Hospital of Brooklyn, Brooklyn, New York 11219, USA. nramchandani@maimonidesmed.org
Journal: Diabetes Technol Ther. 2006 Dec;8(6):663-70.
Abstract URL: Click here to view abstract

10. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study.

Author: Berhe T; Postellon D; Wilson B; Stone R;
Institution: Department of Pediatrics, Loyola University Medical Center, Maywood, IL 60153, USA. debetse@yahoo.com
Journal: Pediatrics. 2006 Jun;117(6):2132-7.
Abstract URL: Click here to view abstract

11. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.

Author: Nimri R; Weintrob N; Benzaquen H; Ofan R; Fayman G; Phillip M;
Institution: Institute for Endocrinology and Diabetes, National Center of Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel.
Journal: Pediatrics. 2006 Jun;117(6):2126-31.
Abstract URL: Click here to view abstract

12. Predictors of glycemic control on insulin pump therapy in children and adolescents with type I diabetes.

Author: Nabhan ZM; Rardin L; Meier J; Eugster EA; Dimeglio LA;
Institution: Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA.
Journal: Diabetes Res Clin Pract. 2006 Dec;74(3):217-21. Epub 2006 May 15.
Abstract URL: Click here to view abstract

13. Comparison of breakfast and bedtime administration of insulin glargine in children and adolescents with Type 1 diabetes.

Author: Karaguzel G; Satilmis A; Akcurin S; Bircan I;
Institution: Pediatric Endocrinolog, Akdeniz University, School of Medicine, Department of Pediatrics, Division of Pediatric Endocrinology, Antalya, Turkey. gulaykg@yahoo.com
Journal: Diabetes Res Clin Pract. 2006 Oct;74(1):15-20. Epub 2006 Apr 18.
Abstract URL: Click here to view abstract

14. Use of pramlintide: the patient's perspective.

Author: Want L;
Institution: MedStar Research Institute, 650 Pennsylvania Ave. SE #50, Washington, DC 20003, USA.
Journal: Diabetes Educ. 2006 May-Jun;32 Suppl 3:111S-118S.
Abstract URL: Click here to view abstract

15. Amylin replacement therapy in patients with type 1 diabetes.

Author: Edelman SV; Caballero L;
Institution: University of California, San Diego, Veterans Affairs Medical Center, 3550 La Jolla Village Drive 111G, San Diego, CA 92161, USA. svedelman@vapop.ucsd.edu
Journal: Diabetes Educ. 2006 May-Jun;32 Suppl 3:119S-127S.
Abstract URL: Click here to view abstract

16. The impact of continuous subcutaneous insulin infusion on health-related quality of life in children and adolescents with type 1 diabetes.

Author: Juliusson PB; Graue M; Wentzel-Larsen T; Sovik O;
Institution: Department of Paediatrics, Haukeland University Hospital, Bergen, Norway. pjul@helse-bergen.no
Journal: Acta Paediatr. 2006 Nov;95(11):1481-7.
Abstract URL: Click here to view abstract

17. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes.

Author: Eugster EA; Francis G;
Institution: Section of Pediatric Endocrinology/Diabetology, Riley Hospital for Children, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA. eeugster@iupui.edu
Journal: Pediatrics. 2006 Oct;118(4):e1244-9.
Abstract URL: Click here to view abstract

18. Unrecognised hypoglycaemia in children and adolescents with type 1 diabetes using the continuous glucose monitoring system: prevalence and contributors.

Author: Wiltshire EJ; Newton K; McTavish L;
Institution: Department of Paediatrics and Child Health, Wellington School of Medicine and Health Sciences, Wellington South, New Zealand. esko.wiltshire@otago.ac.nz
Journal: J Paediatr Child Health. 2006 Dec;42(12):758-63.
Abstract URL: Click here to view abstract

19. Determinants of daily insulin use in Type 1 diabetes.

Author: Muis MJ; Bots ML; Bilo HJ; Hoogma RP; Hoekstra JB; Grobbee DE; Stolk RP;
Institution: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Journal: J Diabetes Complications. 2006 Nov-Dec;20(6):356-60.
Abstract URL: Click here to view abstract

20. Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus.

Author: Mathieu C;
Institution: UZ Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. chantal.mathieu@med.kuleuven.ac.be
Journal: Expert Opin Drug Metab Toxicol. 2006 Oct;2(5):779-91.
Abstract URL: Click here to view abstract

21. OmniPod Insulin Management System: patient perceptions, preference, and glycemic control.

Author: Zisser H; Jovanovic L;
Institution
Journal: Diabetes Care. 2006 Sep;29(9):2175.

22. Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up.

Author: Stettler C; Suter Y; Allemann S; Zwahlen M; Christ ER; Diem P;
Institution: Division of Endocrinology and Diabetes, Department of Social and Preventive Medicine, University of Bern, Bern, Switzerland. christoph.stettler@insel.ch
Journal: J Intern Med. 2006 Sep;260(3):272-80.
Abstract URL: Click here to view abstract